Abstract
Patients with hormone receptor (HR)-positive tumors breast cancer usually experience a relatively low pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). Here, we derived a 10-microRNA risk score (10-miRNA RS)-based model with better performance in the prediction of pCR and validated its relation with the disease-free survival (DFS) in 755 HR-positive breast cancer patients (273, 265, and 217 in the training, internal, and external validation sets, respectively). This model, presented as a nomogram, included four parameters: the 10-miRNA RS found in our previous study, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status, and volume transfer constant (Ktrans). Favorable calibration and discrimination of 10-miRNA RS-based model with areas under the curve (AUC) of 0.865, 0.811, and 0.804 were shown in the training, internal, and external validation sets, respectively. Patients who have higher nomogram score (>92.2) with NAC treatment would have longer DFS (hazard ratio=0.57; 95%CI: 0.39–0.83; P=0.004). In summary, our data showed the 10-miRNA RS-based model could precisely identify more patients who can attain pCR to NAC, which may help clinicians formulate the personalized initial treatment strategy and consequently achieves better clinical prognosis for patients with HR-positive breast cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Asaoka, M., Gandhi, S., Ishikawa, T., and Takabe, K. (2020). Neoadjuvant chemotherapy for breast cancer: past, present, and future. Breast Cancer 14, 117822342098037.
Bear, H.D., Anderson, S., Brown, A., Smith, R., Mamounas, E.P., Fisher, B., Margolese, R., Theoret, H., Soran, A., Wickerham, D.L., et al. (2003). The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 21, 4165–4174.
Board, W.C.O.T.E. (2019). Breast Tumors. Lyon (France): International Agency for Research on Cancer. Available from URL: https://publications.iarc.fr/581.
Chen, B., Tang, H., Liu, X., Liu, P., Yang, L., Xie, X., Ye, F., Song, C., Xie, X., and Wei, W. (2015). MiR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer. Cancer Lett 356, 410–417.
Chen, T., Zhang, N., Moran, M.S., Su, P., Haffty, B.G., and Yang, Q. (2018). Borderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy: a systematic review and meta-analysis. Clin Breast Cancer 18, 1–8.
Cheng, Z., Wu, Z., Shi, G., Yi, Z., Xie, M., Zeng, W., Song, C., Zheng, C., and Shen, J. (2018). Discrimination between benign and malignant breast lesions using volumetric quantitative dynamic contrast-enhanced mr imaging. Eur Radiol 28, 982–991.
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J.P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2019). Pathological complete response and long-term clinical benefit in breast cancer: The ctneobc pooled analysis (vol 384, pg 164, 2014). Lancet 393, 986.
Cuzick, J., Dowsett, M., Pineda, S., Wale, C., Salter, J., Quinn, E., Zabaglo, L., Mallon, E., Green, A.R., Ellis, I.O., et al. (2011). Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 29, 4273–4278.
Di Cosimo, S., Appierto, V., Pizzamiglio, S., Tiberio, P., Iorio, M.V., Hilbers, F., de Azambuja, E., de la Peña, L., Izquierdo, M., Huober, J., et al. (2019). Plasma miRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: results from the NeoALTTO trial. Clin Cancer Res 25, 3887–3895.
Drisis, S., Metens, T., Ignatiadis, M., Stathopoulos, K., Chao, S.L., and Lemort, M. (2016). Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: The impact of breast cancer subtypes on the diagnostic accuracy. Eur Radiol 26, 1474–1484.
Dubsky, P.C., Singer, C.F., Egle, D., Wette, V., Petru, E., Balic, M., Pichler, A., Greil, R., Petzer, A.L., Bago-Horvath, Z., et al. (2020). The endopredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. Eur J Cancer 134, 99–106.
Ferrière, J.P., Assier, I., Curé, H., Charrier, S., Kwiatkowski, F., Achard, J. L., Dauplat, J., and Chollet, P. (1998). Primary chemotherapy in breast cancer. Am J Clin Oncol 21, 117–120.
Filipits, M., Rudas, M., Jakesz, R., Dubsky, P., Fitzal, F., Singer, C.F., Dietze, O., Greil, R., Jelen, A., Sevelda, P., et al. (2011). A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17, 6012–6020.
Fisher, B., Brown, A., Mamounas, E., Wieand, S., Robidoux, A., Margolese, R.G., Cruz Jr, A.B., Fisher, E.R., Wickerham, D.L., Wolmark, N., et al. (1997). Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol 15, 2483–2493.
Gong, C., Yao, Y., Wang, Y., Liu, B., Wu, W., Chen, J., Su, F., Yao, H., and Song, E. (2011). Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 286, 19127–19137.
Gong, C., Tan, W., Chen, K., You, N., Zhu, S., Liang, G., Xie, X., Li, Q., Zeng, Y., Ouyang, N., et al. (2016). Prognostic value of a BCSC-associated microRNA signature in hormone receptor-positive HER2-negative breast cancer. Ebiomedicine 11, 199–209.
Han, B., Huang, J., Han, Y., Hao, J., Wu, X., Song, H., Chen, X., Shen, Q., Dong, X., Pang, H., et al. (2019). The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin. Int J Biol Macromol 125, 544–556.
Iorio, M.V., Ferracin, M., Liu, C.G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65, 7065–7070.
Jain, R.K. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62.
Kasami, M., Uematsu, T., Honda, M., Yabuzaki, T., Sanuki, J., Uchida, Y., and Sugimura, H. (2008). Comparison of estrogen receptor, progesterone receptor and HER-2 status in breast cancer pre- and post-neoadjuvant chemotherapy. Breast 17, 523–527.
Killelea, B.K., Yang, V.Q., Wang, S.Y., Hayse, B., Mougalian, S., Horowitz, N.R., Chagpar, A.B., Pusztai, L., and Lannin, D.R. (2015). Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer: results from the National Cancer Data Base. J Clin Oncol 33, 4267–4276.
Kim, S.J., Jung, K.H., Son, M.K., Park, J.H., Yan, H.H., Fang, Z., Kang, Y. W., Han, B., Lim, J.H., and Hong, S.S. (2017). Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery. Cancer Lett 403, 339–353.
Kobayashi, N., Hikichi, M., Ushimado, K., Sugioka, A., Kiriyama, Y., Kuroda, M., and Utsumi, T. (2017). Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival. Clin Transl Oncol 19, 1232–1240.
Koo, H.R., Cho, N., Song, I.C., Kim, H., Chang, J.M., Yi, A., Yun, B.L., and Moon, W.K. (2012). Correlation of perfusion parameters on dynamic contrast-enhanced MRI with prognostic factors and subtypes of breast cancers. J Magn Reson Imag 36, 145–151.
Kutanzi, K.R., Yurchenko, O.V., Beland, F.A., Checkhun, V.’.F., and Pogribny, I.P. (2011). MicroRNA-mediated drug resistance in breast cancer. Clin Epigenet 2, 171–185.
Li, L., Wang, K., Sun, X., Wang, K., Sun, Y., Zhang, G., and Shen, B. (2015). Parameters of dynamic contrast-enhanced MRI as imaging markers for angiogenesis and proliferation in human breast cancer. Med Sci Monit 21, 376–382.
Makris, A., Powles, T.J., Ashley, S.E., Chang, J., Hickish, T., Tidy, V.A., Nash, A.G., and Ford, H.T. (1998). A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9, 1179–1184.
Makris, A., Powles, T.J., Kakolyris, S., Dowsett, M., Ashley, S.E., and Harris, A.L. (1999). Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer 85, 1996–2000.
McGuire, A., Casey, M.C., Waldron, R.M., Heneghan, H., Kalinina, O., Holian, E., McDermott, A., Lowery, A.J., Newell, J., Dwyer, R.M., et al. (2020). Prospective assessment of systemic microRNAs as markers of response to neoadjuvant chemotherapy in breast cancer. Cancers 12, 1820.
Murphy, B.L., Day, C.N., Hoskin, T.L., Habermann, E.B., and Boughey, J. C. (2018). Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+ subtypes. Ann Surg Oncol 25, 2241–2248.
Pease, A.M., Riba, L.A., Gruner, R.A., Tung, N.M., and James, T.A. (2019). Oncotype DX® recurrence score as a predictor of response to neoadjuvant chemotherapy. Ann Surg Oncol 26, 366–371.
Pickles, M.D., Lowry, M., Manton, D.J., Gibbs, P., and Turnbull, L.W. (2005). Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 91, 1–10.
Prat, A., Galván, P., Jimenez, B., Buckingham, W., Jeiranian, H.A., Schaper, C., Vidal, M., Álvarez, M., Díaz, S., Ellis, C., et al. (2016). Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the Prosigna assay. Clin Cancer Res 22, 560–566.
Rastogi, P., Anderson, S.J., Bear, H.D., Geyer, C.E., Kahlenberg, M.S., Robidoux, A., Margolese, R.G., Hoehn, J.L., Vogel, V.G., Dakhil, S.R., et al. (2008). Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26, 778–785.
Raychaudhuri, M., Bronger, H., Buchner, T., Kiechle, M., Weichert, W., and Avril, S. (2017). MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 162, 511–521.
Reis-Filho, J.S., and Pusztai, L. (2011). Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378, 1812–1823.
Rouzier, R., Perou, C.M., Symmans, W.F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K.R., Stec, J., Ayers, M., Wagner, P., et al. (2005). Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11, 5678–5685.
Saw, P.E., and Song, E.W. (2020). SiRNA therapeutics: a clinical reality. Sci China Life Sci 63, 485–500.
Saw, P.E., Xu, X., Chen, J., and Song, E.W. (2021). Non-coding RNAs: the new central dogma of cancer biology. Sci China Life Sci 64, 22–50.
Sparano, J.A., Crager, M.R., Tang, G., Gray, R.J., Stemmer, S.M., and Shak, S. (2021). Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer. J Clin Oncol 39, 557–564.
Tan, W., Luo, W., Jia, W., Liang, G., Xie, X., Zheng, W., Song, E., Su, F., and Gong, C. (2016). A combination of nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer. Oncotarget 7, 87312–87322.
Tang, H., Song, C., Ye, F., Gao, G., Ou, X., Zhang, L., Xie, X., and Xie, X. (2019). miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer. J Cell Mol Med 23, 8114–8127.
Viallard, C., and Larrivée, B. (2017). Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis 20, 409–426.
Vickers, A.J., Cronin, A.M., Elkin, E.B., and Gonen, M. (2008). Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak 8, 53.
Vincent-Salomon, A., Rousseau, A., Jouve, M., Beuzeboc, P., Sigal-Zafrani, B., Fréneaux, P., Rosty, C., Nos, C., Campana, F., Klijanienko, J., et al. (2004). Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer 40, 1502–1508.
von Minckwitz, G., Untch, M., Nüesch, E., Loibl, S., Kaufmann, M., Kümmel, S., Fasching, P.A., Eiermann, W., Blohmer, J.U., Costa, S.D., et al. (2011). Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the german neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125, 145–156.
von Minckwitz, G., Untch, M., Blohmer, J.U., Costa, S.D., Eidtmann, H., Fasching, P.A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012). Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30, 1796–1804.
von Minckwitz, G., Huang, C.S., Mano, M.S., Loibl, S., Mamounas, E.P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019). Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380, 617–628.
Whitworth, P., Stork-Sloots, L., de Snoo, F.A., Richards, P., Rotkis, M., Beatty, J., Mislowsky, A., Pellicane, J.V., Nguyen, B., Lee, L., et al. (2014). Chemosensitivity predicted by blueprint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST). Ann Surg Oncol 21, 3261–3267.
Yee, D., Demichele, A., Isaacs, C., Symmans, F., Yau, C., Albain, K.S., Hylton, N.M., Forero-Torres, A., Van’t Veer, L.J., Perlmutter, J., et al. (2018). Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL. Cancer Res 78, GS3-08–GS3-08.
Yi, B., Kang, D.K., Yoon, D., Jung, Y.S., Kim, K.S., Yim, H., and Kim, T. H. (2014). Is there any correlation between model-based perfusion parameters and model-free parameters of time-signal intensity curve on dynamic contrast enhanced MRI in breast cancer patients? Eur Radiol 24, 1089–1096.
Yu, F., Deng, H., Yao, H., Liu, Q., Su, F., and Song, E. (2010). MiR-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 29, 4194–4204.
Zhao, Z., Xiao, X., Saw, P.E., Wu, W., Huang, H., Chen, J., and Nie, Y. (2020). Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Sci China Life Sci 63, 180–205.
Acknowledgements
This work was supported by the National Natural Science Foundation of China (92159303, 81621004, 81720108029, 81930081, 91940305, 81672594, 81772836, 81872139, 82072907, and 82003311), Guangdong Science and Technology Department (2020B1212060018 and 2020B1212030004), Clinical Innovation Research Program of Bioland Laboratory (2018GZR0201004), Bureau of Science and Technology of Guangzhou (20212200003), Program for Guangdong Introducing Innovative and Enterpreneurial Teams (2019BT02Y198), the Project of The Beijing Xisike Clinical Oncology Research Foundation (Y-Roche2019/2-0078), the Technology Development Program of Guangdong province (2021A0505030082), the Project of The Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation (2020B1212060018), Sun Yat-Sen Memorial Hospital Cultivation Project for Clinical Research (SYS-C-201805 and SYS-Q-202004), Guangzhou Science and Technology Program (202102010272), and Medical Science and Technology Research Fund of Guangdong Province (A2020391). The authors appreciate the academic support from the AME Breast Cancer Collaborative Group and Claire Verschraegen for her critical review of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Compliance and ethics The author(s) declare that they have no conflict of interest. Presented in poster format at the 55th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31 to June 4, 2019.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Gong, C., Cheng, Z., Yang, Y. et al. A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer. Sci. China Life Sci. 65, 2205–2217 (2022). https://doi.org/10.1007/s11427-022-2104-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-022-2104-3